Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (9): 845-856.doi: 10.19982/j.issn.1000-6621.20230143
• Original Articles • Previous Articles Next Articles
Zhou Wenyong1,2, Wen Zexuan1,2, Gao Mengxian1,2, Li Tao3, Zhang Hui3(), Wang Weibing1,2(
)
Received:
2023-05-06
Online:
2023-09-10
Published:
2023-09-01
Contact:
Wang Weibing, Email: Supported by:
CLC Number:
Zhou Wenyong, Wen Zexuan, Gao Mengxian, Li Tao, Zhang Hui, Wang Weibing. Prediction of the effectiveness and impact of the free healthcare policy for tuberculosis in China[J]. Chinese Journal of Antituberculosis, 2023, 45(9): 845-856. doi: 10.19982/j.issn.1000-6621.20230143
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20230143
参数 | 描述 | 未实施免费医疗情景 | 实施免费医疗情景 | 来源 | ||||
---|---|---|---|---|---|---|---|---|
传播与疗法参数 | ||||||||
β | 结核病传播系数 | 32.202 | / | R0估算[ | ||||
Te | 症状前期结核病患者的早期发现比例 | 0.04 | 0.3 | TBIMS | ||||
pr | 报告患者时被诊断为耐药结核病患者比例 | 0.025 | / | TBIMS | ||||
θe | 早期发现平均延迟时间倒数 | 1 | 2 | TBIMS | ||||
λU | 症状前期时间倒数 | 3/2a | / | 文献[ | ||||
q | 有症状患者住院隔离比例 | 0.8 | 0.95 | TBIMS | ||||
θd | 出现症状到住院隔离平均间隔时间倒数 | 365/14a | 365/4a | 假设 | ||||
pc | 治疗失败的敏感结核病转为耐药结核病比例 | 0.19 | / | TBIMS | ||||
λsf | 敏感结核病治疗失败平均时间倒数 | 3a | 6a | TBIMS | ||||
λrf | 耐药结核病治疗失败平均时间倒数 | 1a | 2a | TBIMS | ||||
ws | 敏感结核病复发率 | 0.0884 | / | 模型拟合 | ||||
wr | 耐药结核病复发率 | 0.00018 | / | 模型拟合 | ||||
c | 敏感结核病转为耐药结核病的转归速率 | 0.00055 | / | 模型拟合 | ||||
π | 全国年出生人数 | 16550004 | / | 统计年鉴[ | ||||
μ | 自然死亡率 | 0.006996 | / | 统计年鉴[ | ||||
μ1 | 敏感结核病病死率 | 0.035 | 0.03 | TBIMS | ||||
μ2 | 耐药结核病病死率 | 0.1 | 0.05 | TBIMS | ||||
αs | 敏感结核病患者接受治疗比例 | 0.95 | 0.98 | TBIMS | ||||
αr | 耐药结核病患者接受治疗比例 | 0.35 | 0.6 | TBIMS | ||||
ηs | 敏感结核病患者治疗完成率 | 1 | 1 | 假设 | ||||
ηr | 耐药结核病患者治疗完成率 | 1 | 1 | 假设 | ||||
γs | 敏感结核病患者治疗失败率 | 0.15 | 0.1 | TBIMS | ||||
γr | 耐药结核病患者治疗失败率 | 0.45 | 0.3 | TBIMS | ||||
λs | 敏感结核病患者治疗速率 | 2/3 | / | TBIMS | ||||
λr | 耐药结核病患者治疗速率 | 1.5 | / | TBIMS | ||||
人口学参数 | ||||||||
N(0) | 2005年初全国总人口数 | 1299879873 | / | 统计年鉴[ | ||||
S(0) | 2005年初敏感结核病患者数 | 975000000 | / | 统计年鉴[ | ||||
E(0) | 2005年初结核分枝杆菌潜伏感染者数 | 325000000 | / | 文献[ | ||||
U(0) | 2005年初未被发现的症状前期结核病患者数 | 1500000 | / | 假设 | ||||
I(0) | 2005年初有症状的结核病患者数 | 50000 | / | 假设 | ||||
Ts(0) | 2005年初正接受治疗的敏感结核病患者数 | 1500000 | / | 假设 | ||||
Tr(0) | 2005年初正接受治疗的耐药结核病患者数 | 0 | / | 假设 | ||||
Rs(0) | 2005年初敏感结核病治愈患者数 | 0 | / | 假设 | ||||
Rr(0) | 2005年初耐药结核病治愈患者数 | 0 | / | 假设 |
年份 | 结核病发病 直接减少例数 | LTBI发病 减少例数 | 结核病发病 间接减少例数 | 增量成功治疗敏感 结核病患者例数 | 增量成功治疗耐药 结核病患者例数 | |||||
---|---|---|---|---|---|---|---|---|---|---|
现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | |
2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2025 | -15001 | -14764 | 687196 | 682172 | 34360 | 34109 | 70444 | 69972 | 62222 | 61688 |
2026 | 32674 | 29875 | 753088 | 742137 | 37654 | 37107 | 51022 | 50805 | 65478 | 64786 |
2027 | 39470 | 34458 | 742795 | 686767 | 37140 | 34338 | 31543 | 31352 | 63539 | 61374 |
2028 | 40421 | 33555 | 722101 | 616773 | 36105 | 30839 | 19258 | 18317 | 60945 | 55706 |
2029 | 40612 | 31679 | 703167 | 554528 | 35158 | 27726 | 11920 | 10218 | 58446 | 49728 |
2030 | 40874 | 29913 | 687520 | 501815 | 34376 | 25091 | 7385 | 5191 | 56192 | 44227 |
2031 | 41261 | 28370 | 674811 | 456995 | 33741 | 22850 | 4371 | 1958 | 54204 | 39402 |
2032 | 41726 | 26979 | 664509 | 418430 | 33225 | 20922 | 2189 | -212 | 52465 | 35238 |
2033 | 42232 | 25678 | 656174 | 384949 | 32809 | 19247 | 481 | -1717 | 50946 | 31661 |
2034 | 42761 | 24440 | 649467 | 355725 | 32473 | 17786 | -943 | -2775 | 49619 | 28589 |
2035 | 43304 | 23258 | 644125 | 330147 | 32206 | 16507 | -2184 | -3517 | 48456 | 25948 |
评估指标 | 模拟情景 | |
---|---|---|
现有递降率 | 加速递降率 | |
结核病发病直接减少例数 | 390333(5.84) | 273441(4.35) |
减少LTBI例数 | 7584954(151.43) | 5730438(121.01) |
结核病发病间接减少例数(进展率为0.1) | 758495(11.35) | 573044(11.44) |
结核病发病间接减少例数(进展率为0.05) | 379248(5.68) | 286522(5.72) |
增量成功治疗敏感结核病患者例数 | 195486(3.37) | 179592(3.79) |
增量成功治疗耐药结核病患者例数 | 62251(152.01) | 49835(154.05) |
免费医疗挽回的总DALY损失 | 2448501(4.42) | 2179554(4.80) |
免费医疗挽回的敏感结核病DALY损失 | 1857114(3.37) | 1706124(3.79) |
免费医疗挽回的耐药结核病DALY损失 | 591387(152.01) | 473430(154.05) |
免费医疗挽回的总社会经济价值(万元) | 27328042(3.71) | 23310346(4.02) |
免费医疗挽回的敏感结核病社会经济价值(万元) | 19482735(2.67) | 17277865(3.00) |
免费医疗挽回的耐药结核病社会经济价值(万元) | 7845306(151.82) | 6032481(154.07) |
免费医疗带来的总净经济收益(万元) | 24896233(3.38) | 21456785(3.70) |
免费医疗带来的敏感结核病净经济收益(万元) | 18159825(2.48) | 16264608(2.82) |
免费医疗带来的耐药结核病净经济收益(万元) | 6736408(130.36) | 5192178(132.61) |
免费医疗总增量投入治疗费用(万元) | 3947282(45.52) | 2998502(45.97) |
免费医疗敏感结核病增量投入治疗费用(万元) | 2459136(35.12) | 1871677(35.54) |
免费医疗耐药结核病增量投入治疗费用(万元) | 1488146(89.15) | 1126825(89.62) |
免费医疗总间接节约治疗费用(万元) | 1515474(17.47) | 1144942(17.55) |
免费医疗敏感结核病间接节约治疗费用(万元) | 1136226(16.23) | 858420(16.31) |
免费医疗耐药结核病间接节约治疗费用(万元) | 379248(22.72) | 286522(22.79) |
免费医疗总净增量投入治疗费用(万元) | 2431809(28.04) | 1853561(28.42) |
免费医疗敏感结核病净增量投入治疗费用(万元) | 1322910(18.89) | 1013257(19.24) |
免费医疗耐药结核病净增量投入治疗费用(万元) | 1108898(66.43) | 840303(66.83) |
年份 | 免费医疗挽回的 总DALY | 免费医疗总净 经济收益(万元) | 免费医疗总净增量 投入费用(万元) | 免费医疗总间接节 约治疗费用(万元) | 免费医疗挽回总社 会经济价值(万元) | 免费医疗总增量投 入治疗费用(万元) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | |
2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2025 | 7283296 | 7233387 | 6359722 | 6317813 | 431223 | 426597 | 137302 | 136298 | 6790946 | 6744410 | 568525 | 562895 |
2026 | 5469153 | 5441891 | 5292525 | 5269824 | 266322 | 261314 | 150467 | 148279 | 5558847 | 5531138 | 416789 | 409593 |
2027 | 3600228 | 3561456 | 3725127 | 3703612 | 236564 | 215414 | 148410 | 137216 | 3961691 | 3919027 | 384975 | 352630 |
2028 | 2408445 | 2269301 | 2631484 | 2504897 | 221078 | 182863 | 144276 | 123231 | 2852562 | 2687760 | 365354 | 306094 |
2029 | 1687606 | 1443162 | 1931471 | 1672709 | 209088 | 157798 | 140493 | 110795 | 2140560 | 1830506 | 349581 | 268592 |
2030 | 1235405 | 913298 | 1472191 | 1097966 | 198570 | 137178 | 137367 | 100263 | 1670761 | 1235145 | 335937 | 237441 |
2031 | 930190 | 560371 | 1146985 | 685143 | 189139 | 119773 | 134827 | 91308 | 1336124 | 804917 | 323966 | 211081 |
2032 | 706372 | 314642 | 893302 | 373364 | 180667 | 105017 | 132769 | 83602 | 1073968 | 478381 | 313436 | 188620 |
2033 | 529657 | 137682 | 676733 | 128368 | 173048 | 92529 | 131104 | 76913 | 849781 | 220896 | 304152 | 169441 |
2034 | 381797 | 7919 | 478453 | -68612 | 166173 | 81983 | 129764 | 71074 | 644626 | 13371 | 295937 | 153057 |
2035 | 252864 | -87568 | 288241 | -228299 | 159935 | 73094 | 128696 | 65963 | 448176 | -155205 | 288631 | 139057 |
年份 | 免费医疗挽回的 总DALY | 免费医疗总净 经济收益(万元) | 免费医疗总净增量 投入费用(万元) | 免费医疗总间接节 约治疗费用(万元) | 免费医疗挽回总社 会经济价值(万元) | 免费医疗总增量投 入治疗费用(万元) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | |
2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2025 | 6692188 | 6647349 | 5968927 | 5930050 | 270869 | 267938 | 102981 | 102229 | 6239796 | 6197988 | 373850 | 370167 |
2026 | 4847112 | 4826428 | 4778497 | 4760107 | 148107 | 145475 | 112856 | 111215 | 4926605 | 4905582 | 260963 | 256690 |
2027 | 2996605 | 2978405 | 3169804 | 3161485 | 127660 | 115952 | 111313 | 102917 | 3297464 | 3277437 | 238974 | 218869 |
2028 | 1829464 | 1740093 | 2048865 | 1964207 | 117953 | 96759 | 108212 | 92428 | 2166818 | 2060966 | 226165 | 189187 |
2029 | 1132369 | 970743 | 1325667 | 1148841 | 110630 | 82450 | 105375 | 83100 | 1436297 | 1231290 | 216005 | 165550 |
2030 | 701576 | 493139 | 844644 | 596163 | 104167 | 70759 | 103030 | 75201 | 948811 | 666922 | 207197 | 145960 |
2031 | 415249 | 186050 | 498154 | 206336 | 98310 | 60905 | 101126 | 68484 | 596464 | 267242 | 199435 | 129390 |
2032 | 207958 | -20122 | 223182 | -83174 | 92998 | 52579 | 99582 | 62705 | 316180 | -30594 | 192579 | 115284 |
2033 | 45670 | -163097 | -14908 | -307249 | 88181 | 45576 | 98333 | 57687 | 73273 | -261673 | 186514 | 103264 |
2034 | -89583 | -263672 | -235054 | -484897 | 83801 | 39713 | 97328 | 53308 | -151253 | -445184 | 181129 | 93021 |
2035 | -207470 | -334072 | -447517 | -626931 | 79797 | 34821 | 96527 | 49475 | -367720 | -592110 | 176324 | 84296 |
年份 | 免费医疗挽回的 总DALY | 免费医疗总净 经济收益(万元) | 免费医疗总净增量 投入费用(万元) | 免费医疗总间接节 约治疗费用(万元) | 免费医疗挽回总社 会经济价值(万元) | 免费医疗总增量投 入治疗费用(万元) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | 现有 递降率 | 加速 递降率 | |
2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2025 | 591109 | 586038 | 390835 | 387803 | 160315 | 158619 | 34360 | 34109 | 551150 | 546422 | 194675 | 192728 |
2026 | 622041 | 615463 | 514071 | 509760 | 118172 | 115796 | 37654 | 37107 | 632242 | 625557 | 155826 | 152903 |
2027 | 603623 | 583052 | 555366 | 542167 | 108861 | 99423 | 37140 | 34338 | 664227 | 641590 | 146001 | 133761 |
2028 | 578980 | 529208 | 582661 | 540726 | 103084 | 86068 | 36105 | 30839 | 685744 | 626794 | 139189 | 116907 |
2029 | 555237 | 472419 | 605845 | 523900 | 98418 | 75316 | 35158 | 27726 | 704263 | 599216 | 133576 | 103043 |
2030 | 533829 | 420159 | 627586 | 501832 | 94364 | 66390 | 34376 | 25091 | 721950 | 568223 | 128740 | 91481 |
2031 | 514940 | 374321 | 648870 | 478833 | 90790 | 58842 | 33741 | 22850 | 739660 | 537675 | 124531 | 81691 |
2032 | 498414 | 334764 | 670158 | 456561 | 87631 | 52414 | 33225 | 20922 | 757789 | 508975 | 120856 | 73335 |
2033 | 483986 | 300779 | 691679 | 435639 | 84829 | 46930 | 32809 | 19247 | 776508 | 482569 | 117638 | 66178 |
2034 | 471380 | 271592 | 713544 | 416305 | 82335 | 42250 | 32473 | 17786 | 795878 | 458555 | 114808 | 60036 |
2035 | 460334 | 246505 | 735795 | 398651 | 80101 | 38254 | 32206 | 16507 | 815896 | 436905 | 112307 | 54762 |
场景 年份 | 减少1例 LTBI者 投入(元) | 直接减少 1例结核病 患者投入 (元) | 直接减少 1例敏感 结核病 患者投入 (元) | 直接减少 1例耐药 结核病 患者投入 (元) | 每挽回 结核病 1 DALY 投入(元) | 每挽回敏 感结核病 1 DALY 投入(元) | 每挽回 耐药结核病 1 DALY 投入(元) | 每投入1元 可挽回社会 经济价值 (元) | 每投入1元 可挽回敏 感结核病 社会经济 价值(元) | 每投入1元 可挽回耐 药结核病 社会经济 价值(元) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
现有递降率 | |||||||||||||||||
2025 | 6275.11 | -287457.46 | -185193.56 | -4274696.01 | 5920.72 | 4047.54 | 27121.05 | 15.75 | 23.04 | 3.44 | |||||||
2026 | 3536.40 | 81507.69 | 46490.41 | 1446651.39 | 4869.53 | 3055.58 | 18997.39 | 20.87 | 33.26 | 5.35 | |||||||
2027 | 3184.79 | 59934.79 | 33172.71 | 1103222.79 | 6570.81 | 4260.16 | 18034.64 | 16.75 | 25.83 | 6.10 | |||||||
2028 | 3061.59 | 54694.33 | 29929.54 | 1020110.43 | 9179.29 | 6447.39 | 17804.37 | 12.90 | 18.37 | 6.65 | |||||||
2029 | 2973.52 | 51483.97 | 27939.05 | 969337.64 | 12389.64 | 9769.81 | 17725.33 | 10.24 | 12.98 | 7.16 | |||||||
2030 | 2888.21 | 48581.13 | 26138.44 | 923459.34 | 16073.31 | 14847.61 | 17676.77 | 8.41 | 9.11 | 7.65 | |||||||
2031 | 2802.84 | 45840.16 | 24437.52 | 880166.84 | 20333.37 | 23674.88 | 17631.24 | 7.06 | 6.07 | 8.15 | |||||||
2032 | 2718.80 | 43298.82 | 22859.45 | 840068.14 | 25576.68 | 44719.37 | 17581.91 | 5.94 | 3.40 | 8.65 | |||||||
2033 | 2637.23 | 40975.65 | 21415.63 | 803459.40 | 32671.77 | 193082.42 | 17527.18 | 4.91 | 0.83 | 9.15 | |||||||
2034 | 2558.61 | 38861.04 | 20100.17 | 770185.50 | 43524.01 | -93545.74 | 17466.70 | 3.88 | -1.80 | 9.67 | |||||||
2035 | 2482.98 | 36933.00 | 18899.61 | 739893.15 | 63249.45 | -38461.89 | 17400.62 | 2.80 | -4.61 | 10.19 | |||||||
累计比值 | 3206.10 | 62300.80 | 34749.36 | 1136360.33 | 9931.82 | 7121.12 | 18750.80 | 11.24 | 14.73 | 7.07 | |||||||
加速递降率 | |||||||||||||||||
2025 | 6253.51 | -288949.56 | -186137.67 | -4297550.39 | 5897.61 | 4030.75 | 27066.40 | 15.81 | 23.13 | 3.44 | |||||||
2026 | 3521.10 | 87469.39 | 49943.34 | 1550413.97 | 4801.90 | 3014.14 | 18814.50 | 21.17 | 33.72 | 5.40 | |||||||
2027 | 3136.65 | 62515.63 | 34513.41 | 1154143.97 | 6048.49 | 3893.09 | 17052.15 | 18.19 | 28.27 | 6.45 | |||||||
2028 | 2964.83 | 54496.57 | 29575.53 | 1025994.43 | 8058.11 | 5560.59 | 16263.53 | 14.70 | 21.30 | 7.28 | |||||||
2029 | 2845.62 | 49810.92 | 26693.64 | 950982.27 | 10934.16 | 8493.45 | 15942.67 | 11.60 | 14.93 | 7.96 | |||||||
2030 | 2733.64 | 45859.71 | 24261.83 | 887790.95 | 15020.11 | 14348.71 | 15801.25 | 9.00 | 9.43 | 8.56 | |||||||
2031 | 2620.89 | 42217.73 | 22018.42 | 829620.26 | 21373.94 | 32736.10 | 15719.56 | 6.72 | 4.39 | 9.14 | |||||||
2032 | 2509.79 | 38925.62 | 19988.74 | 777107.52 | 33376.83 | -261297.58 | 15656.98 | 4.56 | -0.58 | 9.71 | |||||||
2033 | 2403.66 | 36034.00 | 18204.12 | 731054.19 | 67204.76 | -27944.17 | 15602.92 | 2.39 | -5.74 | 10.28 | |||||||
2034 | 2304.68 | 33544.54 | 16665.74 | 691483.00 | 1035237.15 | -15061.52 | 15556.41 | 0.16 | -11.21 | 10.85 | |||||||
2035 | 2213.98 | 31428.00 | 15355.64 | 657923.17 | -83471.47 | -10423.11 | 15518.69 | -2.12 | -17.00 | 11.42 | |||||||
累计比值 | 3234.59 | 67786.50 | 37993.60 | 1229227.46 | 8504.31 | 5937.01 | 17749.26 | 12.58 | 17.06 | 7.18 |
[1] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
[2] |
Waaler H, Geser A, Andersen S. The use of mathematical models in the study of the epidemiology of tuberculosis. Am J Public Health Nations Health, 1962, 52(6): 1002-1013. doi:10.2105/ajph.52.6.1002.
doi: 10.2105/ajph.52.6.1002 URL |
[3] |
Moualeu DP, Nana yakam A, Bowong S, et al. Analysis of a tuberculosis model with undetected and lost-sight cases. Commun Nonlinear Sci Numer Simul, 2016, 41: 48-63. doi:10.1016/j.cnsns.2016.04.012.
doi: 10.1016/j.cnsns.2016.04.012 URL |
[4] |
Rodrigues P, Gomes MG, Rebelo C. Drug resistance in tuberculosis-a reinfection model. Theor Popul Biol, 2007, 71(2): 196-212. doi:10.1016/j.tpb.2006.10.004.
doi: 10.1016/j.tpb.2006.10.004 pmid: 17174368 |
[5] |
Liu S, Li Y, Bi Y, et al. Mixed vaccination strategy for the control of tuberculosis: A case study in China. Math Biosci Eng, 2017, 14(3): 695-708. doi:10.3934/mbe.2017039.
doi: 10.3934/mbe.2017039 pmid: 28092959 |
[6] |
Bhunu CP, Garira W, Mukandavire Z, et al. Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control. J Theor Biol, 2008, 254(3): 633-649. doi:10.1016/j.jtbi.2008.06.023.
doi: 10.1016/j.jtbi.2008.06.023 pmid: 18644386 |
[7] |
Narendran G, Swaminathan S. TB-HIV co-infection: a catastrophic comradeship. Oral Dis, 2016, 22 Suppl 1: 46-52. doi:10.1111/odi.12389.
doi: 10.1111/odi.12389 pmid: 27109272 |
[8] |
ReVelle CS, Lynn WR, Feldmann F. Mathematical models for the economic allocation of tuberculosis control activities in developing nations. Am Rev Respir Dis, 1967, 96(5): 893-909. doi:10.1164/arrd.1967.96.5.893.
doi: 10.1164/arrd.1967.96.5.893 |
[9] | 中华人民共和国卫生部. 结核病防治背景知识及部分免费政策. 2011-03-22. |
[10] |
Ma Y, Horsburgh CR, White LF, et al. Quantifying TB transmission: a systematic review of reproduction number and serial interval estimates for tuberculosis. Epidemiol Infect, 2018, 146(12): 1478-1494. doi:10.1017/S0950268818001760.
doi: 10.1017/S0950268818001760 pmid: 29970199 |
[11] |
Ku CC, MacPherson P, Khundi M, et al. Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease with a Bayesian analysis of prevalence survey and notification data. BMC Med, 2021, 19(1): 298. doi:10.1186/s12916-021-02128-9.
doi: 10.1186/s12916-021-02128-9 |
[12] | 中国统计出版社. 中国统计年鉴. 北京: 中国统计出版社, 2022. |
[13] | 全国结核病流行病学抽样调查技术指导组, 全国结核病流行病学抽样调查办公室. 2000年全国结核病流行病学抽样调查报告. 中国防痨杂志, 2002, 24(2): 65-108. |
[14] | 全国结核病流行病学抽样调查技术指导组. 第四次全国结核病流行病学抽样调查报告. 中华结核和呼吸杂志, 2002, 25(1): 3-7. |
[15] | World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015. |
[16] | World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019. |
[17] |
陈秋奇, 吴超玲, 张培泽, 等. 耐多药结核病患者密切接触者结核分枝杆菌潜伏感染的诊治现状与展望. 结核与肺部疾病杂志, 2022, 3 (6): 517-520. doi:10.19983/j.issn.2096-8493.20220148.
doi: 10.19983/j.issn.2096-8493.20220148 |
[18] |
Houben RMGJ, Menzies NA, Sumner T, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health, 2016, 4(11): e806-e815. doi:10.1016/S2214-109X(16)30199-1.
doi: 10.1016/S2214-109X(16)30199-1 pmid: 27720688 |
[19] |
李雪, 阮云洲, 刘小秋, 等. 2011—2019年中国结核病防治工作经费投入与效益产出分析. 中国防痨杂志, 2021, 43 (7): 702-707. doi:10.3969/j.issn.1000-6621.2021.07.011.
doi: 10.3969/j.issn.1000-6621.2021.07.011 |
[20] |
王岳, 王文灿, 李涛, 等. 不同诊断情景下结核病负担预测的动力学模型研究. 中华流行病学杂志, 2020, 41(4): 580-584. doi:10.3760/cma.j.cn112338-20190706-00497.
doi: 10.3760/cma.j.cn112338-20190706-00497 |
[21] | 贾忠伟, 陆祖宏. 诊断与治疗延误对结核病传播作用. 系统科学与数学, 2016, 36(1): 28-36. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||